Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar:6:439-452.
doi: 10.1200/JGO.19.00170.

Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil

Affiliations
Review

Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil

Maria Isabel Achatz et al. JCO Glob Oncol. 2020 Mar.

Abstract

Purpose: The objective of this review was to address the barriers limiting access to genetic cancer risk assessment and genetic testing for individuals with suspected hereditary breast and ovarian cancer (HBOC) through a review of the diagnosis and management steps of HBOC.

Methods: A selected panel of Brazilian experts in fields related to HBOC was provided with a series of relevant questions to address before the multiday conference. During this conference, each narrative was discussed and edited by the entire group, through numerous drafts and rounds of discussion, until a consensus was achieved.

Results: The authors propose specific and realistic recommendations for improving access to early diagnosis, risk management, and cancer care of HBOC specific to Brazil. Moreover, in creating these recommendations, the authors strived to address all the barriers and impediments mentioned in this article.

Conclusion: There is a great need to expand hereditary cancer testing and counseling in Brazil, and changing current policies is essential to accomplishing this goal. Increased knowledge and awareness, together with regulatory actions to increase access to this technology, have the potential to improve patient care and prevention and treatment efforts for patients with cancer across the country.

PubMed Disclaimer

Conflict of interest statement

Maria Isabel Achatz

Speakers' Bureau: AstraZeneca, MSD Oncology

Rodrigo Guindalini

Employment: CLION, Grupo CAM, Oncologia D'or

Stock and Other Ownership Interests: Mendelics Análise Genômica

Consulting or Advisory Role: AstraZeneca Brazil, Merck Brazil

Speakers' Bureau: AstraZeneca, Roche, MSD, Bayer, Merck, Teva, Boehringer Ingelheim, Bristol-Myers Squibb

Travel, Accommodations, Expenses: AstraZeneca, Roche

Angelica Nogueira-Rodrigues

Honoraria: Roche, MSD, AstraZeneca

Consulting or Advisory Role: Roche, AstraZeneca, MSD, Eisai

Patricia Ashton-Prolla

Research Funding: AstraZeneca Brazil (Inst)

No other potential conflicts of interest were reported.

References

    1. Szabo CI, King MC. Inherited breast and ovarian cancer. Hum Mol Genet. 1995;4:1811–1817. - PubMed
    1. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12:68–78. - PMC - PubMed
    1. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130. - PMC - PubMed
    1. Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269–275. - PMC - PubMed
    1. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–2416. - PubMed

Publication types